Acoustic Radiation Force Impulse-Imaging in Comparison to Transient Elastography for Liver Fibrosis Staging in HCV
- Conditions
- Chronic Hepatitis C
- Registration Number
- NCT01113814
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Brief Summary
This study will evaluate the effectiveness of Acoustic Radiation Force Impulse (ARFI)- Imaging compared to Transient Elastography (FibroScan) in differentiating liver fibrosis in patients with chronic hepatitis C. Patients who are scheduled to have a liver biopsy will also undergo ARFI and FibroScan testing. The liver biopsy will be used as the reference method. The target sample size is 433.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
- Male or female, 18-79 years old
- Written consent
- Chronic Hepatitis C infection
- Liver biopsy planned or performed within the last six months
- In addition, 10 patients/center with proven liver cirrhosis without present liver biopsy can be included
- Consuming illness (HIV infection, malignoma)
- Comorbidities associated to HCV (HBV, NASH, hemochromatosis, primary sclerosing cholangitis, primary biliary cirrhosis
- Antiviral therapy between liver biopsy and study inclusion
- Pacemaker or heart defibrillator
- Pregnancy or lactation
- Liver transplantation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Non-inferiority of AUROCs of Acoustic Radiation Force Impulse (ARFI)- Imaging to Transient Elastography (Fibroscan) for assessment of liver fibrosis in patients with chronic hepatitis C using liver biopsy as the reference standard. The diagnostic accuracy measured with the Area under the ROC curve (AUROC) is calculated for Acoustic Radiation Force Impulse (ARFI)- Imaging and Transient Elastography (Fibroscan) using histology obtained by liver biopsy as reference method in patients infected with chronic hepatitis C. The ROC curve represents sensitivity versus 1-specificity for all possible cut-off values for prediction of the different fibrosis stages, respectively. The areas under the curves (AUROC) as well as 95 % CI of AUROC are calculated.
- Secondary Outcome Measures
Name Time Method Comparison of AUROC of ARFI-Imaging and Transient Elastography with FibroMax (liver fibrosis marker) Comparison of AUROC of ARFI and Transient Elastography with the European Liver Fibrosis-Group Marker (ELF) Evaluation of a combination of non-invasive methods for optimising AUROC for the assessment of liver fibrosis Evaluation of factors associated with measurement failure of ARFI-Imaging and Transient Elastography Assessment of center variability of results
Trial Locations
- Locations (9)
Erasmus Medical Center
🇳🇱Rotterdam, Netherlands
Bordeaux University Hospital
🇫🇷Bordeaux, France
Universitätsklinikum Düsseldorf
🇩🇪Düsseldorf, Germany
Universitätsklinikum Erlangen
🇩🇪Erlangen, Germany
Institut für Interdisziplinäre Medizin
🇩🇪Hamburg, Germany
Klinikum der J.W. Goethe-Universität
🇩🇪Frankfurt am Main, Germany
Universitätsklinikum Leipzig
🇩🇪Leipzig, Germany
Klinikum der Ludwig-Maximilians-Universität-Campus Großhadern
🇩🇪München, Germany
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany